Insulin (Humulin® R U-100)

DRUG4 trials

Conditions

Alzheimer DiseaseAlzheimer Disease, Early OnsetAlzheimer's DiseaseAmnestic Mild Cognitive ImpairmentCognitive ImpairmentGestational Diabetes Mellitus (GDM)Mild Cognitive Impairment

Phase 2

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

CompletedNCT01767909

University of Southern CaliforniaAlzheimer's Disease, Amnestic Mild Cognitive Impairment

Start: 2014-01-08End: 2018-12-11Updated: 2024-11-20

SNIFF - 3-Week Aptar CPS Device

WithdrawnNCT05006599

Wake Forest University Health SciencesAlzheimer Disease, Early Onset, Cognitive Impairment, Mild Cognitive Impairment

Start: 2025-05-31End: 2031-05-31Updated: 2025-07-28

SNIFF - Combo INI+EMPA Trial

CompletedNCT05081219

Wake Forest University Health SciencesAlzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment

Start: 2021-09-14End: 2024-09-17Updated: 2025-10-21

Unknown Phase

Insulin Versus Oral Hypoglycemic Agents in Gestational Diabetes Mellitus

CompletedNCT07582471

Dr Mudassar Saeed PansotaGestational Diabetes Mellitus (GDM)

Start: 2025-10-08End: 2026-04-07Updated: 2026-05-14

Related Papers

A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.

2025-10-011 citations

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.

2021-01-0160 citations

Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia

JAMA Neurology2020-06-22336 citations

Insulin (Humulin® R U-100)

Sponsors

Conditions

Phase 2

Unknown Phase

Related Papers